Codexis Announces Workforce Reduction and New CEO

Codexis ( (CDXS) ) has shared an announcement.

On November 6, 2025, Codexis announced a 24% workforce reduction to streamline operations and focus on its ECO Synthesis platform, expecting to incur a $3.5 million expense in the fourth quarter of 2025. Additionally, the company appointed Alison Moore as the new CEO, succeeding Stephen Dilly, who will remain as Chair of the Board. Codexis also signed a $37.8 million Supply Assurance Agreement with Merck, which, along with organizational changes, is expected to extend its cash runway through 2027.

The most recent analyst rating on (CDXS) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Codexis stock, see the CDXS Stock Forecast page.

Spark’s Take on CDXS Stock

According to Spark, TipRanks’ AI Analyst, CDXS is a Neutral.

Codexis’s overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues, persistent losses, and financial instability. While the earnings call provided some positive insights, including revenue growth and improved margins, these are overshadowed by the company’s operational inefficiencies and bearish technical indicators. The negative valuation metrics further contribute to the low score.

To see Spark’s full report on CDXS stock, click here.

More about Codexis

Codexis, Inc. is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing. The company leverages its proprietary CodeEvolver technology platform to develop high-performance enzymes that address challenges in small molecule pharmaceuticals manufacturing and nucleic acid synthesis. Codexis is currently focusing on its ECO Synthesis platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route.

Average Trading Volume: 850,113

Technical Sentiment Signal: Sell

Current Market Cap: $195.9M

For an in-depth examination of CDXS stock, go to TipRanks’ Overview page.